Individuals with the highest antibody levels in the week prior to the second vaccine dose experienced more side effects from the second dose. For those receiving either mRNA vaccine, local side effects were more common after the first vaccine dose, whereas systemic side effects were more common after the second dose. Similar antibody levels were seen among those vaccinated with Moderna ( n = 29) and Pfizer-BioNTech ( n = 137). Naïve individuals ( n = 161) attained high S antibody levels after the second dose. Participants with prior SARS-CoV-2 infection ( n = 7) generated high S antibody levels after the first vaccine dose. Most DBS (99.6%, 507/509) were suitable for testing. Three DBS were collected by each of 168 participants pre- and/or postvaccination and tested with a multiplex microsphere immunoassay (MIA) that separately measures IgG antibodies to SARS-CoV-2 spike-S1 and nucleocapsid antigens. Participants received a DBS collection kit, self-collection instructions, and a brief questionnaire. As COVID-19 vaccine deployment began in early 2021, we rapidly enrolled laboratory employees in a study to evaluate IgG antibody levels following vaccination. Dried blood spots (DBS) are a suitable alternative because they can be self-collected and stored/shipped at room temperature. However, collection of venous blood requires trained medical staff. Serosurveys can determine the extent and spread of a pathogen in populations.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |